Lantheus Holdings LNTH Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Cardiology | $84.63M+6.8% | —— | —— | —— | $79.21M— | |
| Definity | $84.63M+6.8% | $85.31M-1.0% | $81.79M+6.3% | $83.94M+7.5% | $79.21M+3.5% | |
| Licenseand Royalty Revenues | $7.48M+28.0% | $17.37M+479% | $7.33M+77.3% | $3.5M+162% | $5.85M+783% | |
| Neuraceq | $35.44M— | $31.01M— | $20.44M— | $0— | $0— | |
| Neurology | $35.44M— | —— | —— | —— | $0— | |
| Oncology | $240.92M-6.5% | —— | —— | —— | $257.65M— | |
| PYLARIFY | $240.92M-6.5% | $240.2M-9.7% | $240.62M-7.4% | $250.64M-8.3% | $257.65M-0.5% | |
| SPECT Business | $0-100% | —— | —— | —— | $25.15M— | |
| Strategic Partnerships And Other | $16.34M+52.1% | $23.34M+203% | $13.71M-10.1% | $11.59M+32.8% | $10.75M+65.1% | |
| Revenue by Geography | ||||||
| Non Us | $22.91M+52.6% | —— | —— | —— | $15.01M+22.0% | |
| US | $354.43M-0.9% | —— | —— | —— | $357.76M-3.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Lantheus Holdings break its business down?
- Lantheus Holdings (LNTH) reports revenue by product across 9 parts — Cardiology, Definity, Licenseand Royalty Revenues, Neuraceq and Neurology. Each is extracted from the segment footnotes and tracked over time.
- Where does Lantheus Holdings's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Lantheus Holdings's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
